Fri, Oct 11, 2024
[Archive]
Volume 32, Issue 151 (March & April 2024)
J Adv Med Biomed Res 2024, 32(151): 135-143 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mosaffa F, Valinezhad Sani F, Ghofrani S, Kamalian S, Ehtesham Gharaee M. Evaluating the Anti-Migratory Effect of Fucoxanthin in Human Cisplatin-Resistant Ovarian Cancer Cells. J Adv Med Biomed Res 2024; 32 (151) :135-143
URL: http://journal.zums.ac.ir/article-1-7340-en.html
URL: http://journal.zums.ac.ir/article-1-7340-en.html
Fatemeh Mosaffa * 
1, Fatemeh Valinezhad Sani2 , Shiva Ghofrani3 , Safa Kamalian3 , Melika Ehtesham Gharaee3
1, Fatemeh Valinezhad Sani2 , Shiva Ghofrani3 , Safa Kamalian3 , Melika Ehtesham Gharaee3
1- Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran , mosaffaf@mums.ac.ir
2- Department of Laboratory Sciences, School of Paramedical and RehabilitationSciences, Mashhad University of Medical Sciences, Mashhad, Iran
3- Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
2- Department of Laboratory Sciences, School of Paramedical and RehabilitationSciences, Mashhad University of Medical Sciences, Mashhad, Iran
3- Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract: (201 Views)
Background & Objective: Ovarian cancer ranks among the most prevalent gynecologic cancers in women with the majority of patients experiencing a recurrent type and developing treatment resistance. Resistance to chemotherapy drugs has been observed to trigger epithelial-mesenchymal transition (EMT), which leads to the acquisition of metastatic properties. Thus, targeting the molecular mechanism of EMT may lead to novel interventions against metastatic disease. In this research, the suppressive impacts of fucoxanthin, as a natural compound, were examined on cell migration and expression of key EMT-related markers in ovarian cancer cells which were sensitive and resistant to cisplatin.
Materials & Methods: To determine the non-toxic concentrations of fucoxanthin for migration assay, the MTT assay was conducted. To assess the anti-migratory capacity of fucoxanthin in ovarian cancer cells which were sensitive and resistant to cisplatin, a wound-healing migration test was done in the presence of non-toxic concentrations of fucoxanthin. RT-qPCR was utilized to examine the impact of fucoxanthin on the mRNA expression of E-cadherin, vimentin and α- SMA (as EMT-related markers) in ovarian cancer cells.
Results: Fucoxanthin at concentrations of (1 and 2.5 μM) downregulated the expression of α–SMA in cisplatin-resistant ovarian cancer cells and inhibited migration in ovarian cancer cell lines.
Conclusion: Fucoxanthin exhibited remarkable efficacy in inhibiting migration in in ovarian cancer cells which were sensitive and resistant to cisplatin. However, more research is required to ascertain the clinical advantages linked to utilizing fucoxanthin in the treatment of cisplatin-resistant ovarian cancers.
Materials & Methods: To determine the non-toxic concentrations of fucoxanthin for migration assay, the MTT assay was conducted. To assess the anti-migratory capacity of fucoxanthin in ovarian cancer cells which were sensitive and resistant to cisplatin, a wound-healing migration test was done in the presence of non-toxic concentrations of fucoxanthin. RT-qPCR was utilized to examine the impact of fucoxanthin on the mRNA expression of E-cadherin, vimentin and α- SMA (as EMT-related markers) in ovarian cancer cells.
Results: Fucoxanthin at concentrations of (1 and 2.5 μM) downregulated the expression of α–SMA in cisplatin-resistant ovarian cancer cells and inhibited migration in ovarian cancer cell lines.
Conclusion: Fucoxanthin exhibited remarkable efficacy in inhibiting migration in in ovarian cancer cells which were sensitive and resistant to cisplatin. However, more research is required to ascertain the clinical advantages linked to utilizing fucoxanthin in the treatment of cisplatin-resistant ovarian cancers.
Type of Study: Original Article |
Subject:
Pharmacology
Received: 2023/09/3 | Accepted: 2024/03/4 | Published: 2024/03/2
Received: 2023/09/3 | Accepted: 2024/03/4 | Published: 2024/03/2
References
1. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280-304. [DOI:10.3322/caac.21559] [PMID]
2. Ramos FS, Wons L, Cavalli IJ, Ribeiro E. Epithelial-mesenchymal transition in cancer: An overview. Integr Cancer Sci Ther. 2017;4(4). [DOI:10.15761/ICST.1000243]
3. Liang Y, McDonnell S, Clynes M. Examining the relationship between cancer invasion/metastasis and drug resistance. Curr Cancer Drug Targets. 2002;2(3):257-77. [DOI:10.2174/1568009023333872] [PMID]
4. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28:15-33. [DOI:10.1007/s10555-008-9169-0] [PMID]
5. Battaglia RA, Delic S, Herrmann H, Snider NT. Vimentin on the move: new developments in cell migration. F1000Res. 2018;7. [DOI:10.12688/f1000research.15967.1] [PMID] [PMCID]
6. Chen J, Yang P, Xiao Y, et al. Overexpression of α-sma-positive fibroblasts (CAFs) in nasopharyngeal carcinoma predicts poor prognosis. J Cancer. 2017;8(18):3897. [DOI:10.7150/jca.20324] [PMID] [PMCID]
7. Jeanes A, Gottardi C, Yap A. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene. 2008;27(55):6920-9. [DOI:10.1038/onc.2008.343] [PMID] [PMCID]
8. Lee M, Vasioukhin V. Cell polarity and cancer-cell and tissue polarity as a non-canonical tumor suppressor. J Cell Sci. 2008;121(8):1141-50. [DOI:10.1242/jcs.016634] [PMID]
9. De Arcangelis A, Hamade H, Alpy F, et al. Hemidesmosome integrity protects the colon against colitis and colorectal cancer. Gut. 2017;66(10):1748-60. [DOI:10.1136/gutjnl-2015-310847] [PMID] [PMCID]
10. Bigdelou Z, Mortazavi Y, Saltanatpour Z, et al. Role of Oct4-Sox2 complex decoy oligodeoxynucleotides strategy on reverse epithelial to mesenchymal transition (EMT) induction in HT29 ShE encompassing enriched cancer stem like cells. Mol Biol Rep. 2020;47(3):1859-1869. [DOI:10.1007/s11033-020-05280-2] [PMID]
11. Saltanatpour Z, Johari B , Alizadeh A, et al. Enrichment of cancer stem‐like cells by the induction of epithelial‐mesenchymal transition using lentiviral vector carrying E‐cadherin shRNA in HT29 cell line. J Cell Physiol. 2019;234(12):22935-22946. [DOI:10.1002/jcp.28855] [PMID]
12. Khaw YS, Yusoff FM, Tan HT, et al. The critical studies of fucoxanthin research trends from 1928 to june 2021: A bibliometric review. Mar Drugs. 2021;19(11):606. [DOI:10.3390/md19110606] [PMID] [PMCID]
13. Hitoe S, Shimoda H. Seaweed fucoxanthin supplementation improves obesity parameters in mild obese Japanese subjects. Function Foods Health Dis. 2017;7(4):246-62. [DOI:10.31989/ffhd.v7i4.333]
14. Krinsky NI, Johnson EJ. Carotenoid actions and their relation to health and disease. Mol Aspects Med. 2005;26(6):459-516. [DOI:10.1016/j.mam.2005.10.001] [PMID]
15. Thiyagarasaiyar K, Goh BH, Jeon YJ, Yow YY. Algae metabolites in cosmeceutical: An overview of current applications and challenges. Mar Drugs. 2020;18(6):323. [DOI:10.3390/md18060323] [PMID] [PMCID]
16. Muthuirulappan S, Francis SP. Anti-cancer mechanism and possibility of nano-suspension formulation for a marine algae product fucoxanthin. Asian Pac J Cancer Prev. 2013;14(4):2213-6. [DOI:10.7314/APJCP.2013.14.4.2213] [PMID]
17. Ye G, Lu Q, Zhao W, Du D, Jin L, Liu Y. Fucoxanthin induces apoptosis in human cervical cancer cell line HeLa via PI3K/Akt pathway. Tumor Biology. 2014;35:11261-7. [DOI:10.1007/s13277-014-2337-7] [PMID]
18. Mauro C, Zazzeroni F, Papa S, Bubici C, Franzoso G. The NF-κB transcription factor pathway as a therapeutic target in cancer: methods for detection of NF-κB activity. Inflammation and Cancer: Methods and Protocols: Volume 2: Molecular Analysis and Pathways. 2009:169-207. [DOI:10.1007/978-1-60327-530-9_10] [PMID]
19. Deeb D, Gao X, Dulchavsky SA, Gautam SC. CDDO-Me induces apoptosis and inhibits Akt, mTOR and NF-κB signaling proteins in prostate cancer cells. Anticancer Res. 2007;27(5A):3035-44
20. Huber MA, Azoitei N, Baumann B, et al. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest. 2004;114(4):569-8 [DOI:10.1172/JCI200421358] [PMID] [PMCID]
21. Sani FV, Palizban A, Mosaffa F, Jamialahmadi K. Glucosamine reverses drug resistance in MRP2 overexpressing ovarian cancer cells. Eur J Pharmacol. 2020;868:172883. [DOI:10.1016/j.ejphar.2019.172883] [PMID]
22. Sani FV, Kamalian S, Abdi H, Ghofrani S, Boustan A, Mosaffa F. Fucoxanthin inhibits the proliferation of ABCC2-over expressing cisplatin-resistance ovarian cancer cells via inducing apoptosis. Pharm Sci. 2022;29(3):320-7. [DOI:10.34172/PS.2022.44]
23. Sambasivan S. Epithelial ovarian cancer: Review article. Cancer Treat Res Commun. 2022;33:100629. [DOI:10.1016/j.ctarc.2022.100629] [PMID]
24. Yeung TL, Leung CS, Yip KP, Au Yeung CL, Wong ST, Mok SC. Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: cell and molecular processes in cancer metastasis. Am J Physiol Cell Physiol. 2015;309(7):C444-56. [DOI:10.1152/ajpcell.00188.2015] [PMID] [PMCID]
25. Motohara T, Masuda K, Morotti M, et al. An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment. Oncogene. 2019;38(16):2885-98. [DOI:10.1038/s41388-018-0637-x] [PMID] [PMCID]
26. Manivasagan P, Bharathiraja S, Santha Moorthy M, et al. Marine natural pigments as potential sources for therapeutic applications. Crit Rev Biotechnol. 2018;38(5):745-61. [DOI:10.1080/07388551.2017.1398713] [PMID]
27. Pajot A, Hao Huynh G, Picot L, Marchal L, Nicolau E. Fucoxanthin from algae to human, an extraordinary bioresource: Insights and advances in up and downstream processes. Mar Drugs. 2022;20(4):222. [DOI:10.3390/md20040222] [PMID] [PMCID]
28. Peng J, Yuan JP, Wu CF, Wang JH. Fucoxanthin, a marine carotenoid present in brown seaweeds and diatoms: Metabolism and bioactivities relevant to human health. Mar Drugs. 2011;9(10):1806-28. [DOI:10.3390/md9101806] [PMID] [PMCID]
29. Mohibbullah M, Haque MN, Sohag AAM, et al. A systematic review on marine algae-derived fucoxanthin: An update of pharmacological insights. Mar Drugs. 2022;20(5):279. [DOI:10.3390/md20050279] [PMID] [PMCID]
30. Yu R, Yu Rt, Liu Z. Inhibition of two gastric cancer cell lines induced by fucoxanthin involves downregulation of Mcl-1 and STAT3. Hum Cell. 2018;31:50-63. [DOI:10.1007/s13577-017-0188-4] [PMID]
31. Kumar SR, Hosokawa M, Miyashita K. Fucoxanthin: a marine carotenoid exerting anti-cancer effects by affecting multiple mechanisms. Mar Drugs. 2013;11(12):5130-47. [DOI:10.3390/md11125130] [PMID] [PMCID]
32. Huber MA, Azoitei N, Baumann B, et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest. 2004;114(4):569-81. [DOI:10.1172/JCI200421358] [PMID] [PMCID]
33. Wu Y, Zhou BP. New insights of epithelial‐mesenchymal transition in cancer metastasis. Acta Biochim Biophys Sin. 2008;40(7):643-50. [DOI:10.1111/j.1745-7270.2008.00443.x] [PMID] [PMCID]
34. Lu L, Zhou D, Jiang X, Song K, Li K, Ding W. Loss of E-cadherin in multidrug resistant breast cancer cell line MCF-7/Adr: possible implication in the enhanced invasive ability. Eur Rev Med Pharmacol Sci. 2012;16(9):1271-9
35. Saxena M, Stephens MA, Pathak H, Rangarajan A. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2011;2(7):e179. [DOI:10.1038/cddis.2011.61] [PMID] [PMCID]
36. Zhan S, Liu Z, Zhang M. et al. Overexpression of B7-H3 in α-SMA-positive fibroblasts is associated with cancer progression and survival in gastric adenocarcinomas. Front Oncol. 2020;9:1466. [DOI:10.3389/fonc.2019.01466] [PMID] [PMCID]
37. Liu Y, Zheng J, Zhang Y, et al. Fucoxanthin activates apoptosis via inhibition of PI3K/Akt/mTOR pathway and suppresses invasion and migration by restriction of p38-MMP-2/9 pathway in human glioblastoma cells. Neurochem Res. 2016;41:2728-51. [DOI:10.1007/s11064-016-1989-7] [PMID]
38. Wang W, Fu C, Lin M, et al. Fucoxanthin prevents breast cancer metastasis by interrupting circulating tumor cells adhesion and transendothelial migration. Front Pharmacol. 2022;13:960375. [DOI:10.3389/fphar.2022.960375] [PMID] [PMCID]
39. Ming JX, Wang ZC, Huang Y, et al. Fucoxanthin extracted from Laminaria Japonica inhibits metastasis and enhances the sensitivity of lung cancer to Gefitinib. Ethnopharmacol. 2021;265:113302. [DOI:10.1016/j.jep.2020.113302] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
